6600 — SciClone Pharmaceuticals (Holdings) Cashflow Statement
0.000.00%
Last trade - 00:00- HK$11.30bn
- HK$9.17bn
- CNY3.16bn
- 100
- 53
- 99
- 98
Annual cashflow statement for SciClone Pharmaceuticals (Holdings), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | 661 | 817 | 1,026 | 940 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 20.5 | 104 | 127 | 444 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 314 | -53.5 | -231 | -319 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,032 | 981 | 1,029 | 1,184 | — |
| Capital Expenditures | -32.6 | -469 | -191 | -196 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -120 | -201 | 64.6 | -829 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -152 | -671 | -126 | -1,026 | — |
| Financing Cash Flow Items | -212 | -2,183 | -3.18 | 0 | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -235 | -53.3 | 116 | -670 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 644 | 199 | 1,009 | -456 | — |